Randall Michael Giuffre
Known title: DirectorCIK: 0001759822
Randall Michael Giuffre's purchase track record
How the stock did after each of Randall Michael Giuffre's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 29, 2022
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+119.4%
3 months: +31.6%
Beat the S&P 500
67%
median +110.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/23/2023 | DMAC | $254K | -34.1% | -32.9% | +9.3% |
| 12/7/2022 | DMAC | $113K | +31.6% | +119.4% | +8.5% |
| 11/29/2022 | DMAC | $85K | +44.2% | +134.2% | +6.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DMAC | ▲ Buy | Grant | 6,175 | $52K | 1/2/2026 | View on chart |
| DMAC | ▲ Buy | Option Exercise | 12,000 | $25K | 2/13/2025 | View on chart |
| DMAC | ▲ Buy | Option Exercise | 5,000 | $18K | 2/13/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 10,861 | $58K | 1/2/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 19,196 | $54K | 1/2/2024 | View on chart |
| DMAC | ▼ Sell | Gift | 15,000 | $0 | 6/23/2023 | View on chart |
| DMAC | ▲ Buy | Open Market | 65,000 | $254K | 6/23/2023 | View on chart |
| DMAC | ▲ Buy | Grant | 35,130 | $54K | 1/3/2023 | View on chart |
| DMAC | ▲ Buy | Open Market | 37,079 | $53K | 12/9/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 20,000 | $28K | 12/8/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 22,574 | $32K | 12/7/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 2,300 | $3K | 12/6/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 819 | $975 | 12/1/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 46,133 | $55K | 12/1/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 2,970 | $4K | 11/30/2022 | View on chart |
| DMAC | ▲ Buy | Open Market | 18,125 | $22K | 11/29/2022 | View on chart |
| DMAC | ▲ Buy | Grant | 15,026 | $54K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.